<DOC>
	<DOCNO>NCT01612221</DOCNO>
	<brief_summary>This phase II intervention propose new melanoma chemoprevention agent . The investigator believe oxidative stress/damage nevus probable indication melanoma risk , propose reduce melanoma risk human inferred protection nevi ultraviolet light ( UV ) -induced oxidative change . The investigator 1 ) evaluate whether administration NAC around time UV exposure reduce melanoma risk high-risk patient population genetic susceptibility UV-induced oxidative stress , 2 ) examine key genetic variant identify individual likely benefit chemoprotection .</brief_summary>
	<brief_title>Oral N-acetylcysteine Protection Human Nevi Against UV-induced Oxidative Stress/Damage Vivo</brief_title>
	<detailed_description />
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Must least 2 nevus ( &gt; 6 mm diameter ) clinically suspicious melanoma biopsied . Must able receive inform consent sign approve consent form conform federal institutional guideline . The patient minor ( &lt; 18 year old ) . The patient speak/understand English Spanish . ( NOTE : A Spanish consent form certify interpreter make available need ) The patient pregnant . ( NOTE : All female patient hysterectomy postmenopausal ( i.e . postmenopausal 1 year childbearing potential ) urine pregnancy test . ) The patient prisoner , critically mentally ill , otherwise incapacitate consider vulnerable . The patient history allergic reaction NAC . The patient history severe asthma . The patient take NAC oral antioxidant . The patient recent history ( i.e. , 3 month ) sunless tan ( tan bed ) extensive sunburn .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>